Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$144.13 USD
-1.50 (-1.03%)
Updated Aug 7, 2024 03:59 PM ET
After-Market: $144.02 -0.11 (-0.08%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Neurocrine Biosciences, Inc. [NBIX]
Reports for Purchase
Showing records 161 - 180 ( 312 total )
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker - Week Ending 9/18/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Sustained Motor Function Improvement in Phase 1 Gene Therapy Trial Supports NBIb-1817 Progress in PD; Reit $140 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Worth The Wait; Encouraging VY-AADC 2-/3-Year Update Puts Durability On Display
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Delving Virtually Into the Epilepsy Therapeutics Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker - Week Ending 8/21/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Ingrezza Commercial Execution Full Steam Ahead, Ongentys Launch in PD Anticipated 3Q20; PT to $140
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Neurocrine Biosciences, Inc.
Industry: Medical - Drugs
Neurology Prescription Sales Tracker -- Week Ending 7/24/20
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L